Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach

This article was originally published in The Pink Sheet Daily

Executive Summary

The failure of Clavis Pharma's and Clovis Oncology's novel potential pancreatic cancer therapy CP-4126/CO-101 in the pivotal LEAP trial was associated with the surprising failure of a novel personalized medicine approach to treating the devastating disease.

You may also be interested in...



Clovis Highlights Pipeline Turnaround Going Into 2014

The small oncology company has recovered from previous setbacks and is now anticipating a strong year to come as it moves two drugs into later-stage development and pivotal trials.

Clovis Highlights Pipeline Turnaround Going Into 2014

The small oncology company has recovered from previous setbacks and is now anticipating a strong year to come as it moves two drugs into later-stage development and pivotal trials.

Biopharma Dealmaking Quarterly Statistics, Q2 2013

Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel